CLARITEV CORP (CTEV) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:CTEV - US62548M2098 - Common Stock
37.96 USD
+0.51 (+1.36%)
37.96 USD
0 (0%)
Overall CTEV gets a fundamental rating of 2 out of 10. We evaluated CTEV against 35 industry peers in the Health Care Technology industry. CTEV may be in some trouble as it scores bad on both profitability and health. CTEV does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
CTEV had negative earnings in the past year.
CTEV had a positive operating cash flow in the past year.
In the past 5 years CTEV reported 4 times negative net income.
Each year in the past 5 years CTEV had a positive operating cash flow.
1.2 Ratios
The Return On Assets of CTEV (-6.85%) is better than 65.71% of its industry peers.
The Return On Invested Capital of CTEV (0.82%) is better than 62.86% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CTEV is below the industry average of 6.61%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.85% | ||
| ROE | N/A | ||
| ROIC | 0.82% |
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 5.21%, CTEV is in the better half of the industry, outperforming 68.57% of the companies in the same industry.
CTEV's Operating Margin has declined in the last couple of years.
CTEV's Gross Margin of 74.72% is fine compared to the rest of the industry. CTEV outperforms 74.29% of its industry peers.
CTEV's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.21% | ||
| PM (TTM) | N/A | ||
| GM | 74.72% |
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CTEV is destroying value.
The number of shares outstanding for CTEV remains at a similar level compared to 1 year ago.
CTEV has less shares outstanding than it did 5 years ago.
The debt/assets ratio for CTEV is higher compared to a year ago.
2.2 Solvency
CTEV has an Altman-Z score of -0.35. This is a bad value and indicates that CTEV is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.35, CTEV perfoms like the industry average, outperforming 45.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.35 |
ROIC/WACC0.12
WACC6.74%
2.3 Liquidity
A Current Ratio of 1.21 indicates that CTEV should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.21, CTEV is doing worse than 77.14% of the companies in the same industry.
A Quick Ratio of 1.21 indicates that CTEV should not have too much problems paying its short term obligations.
CTEV has a Quick ratio of 1.21. This is in the lower half of the industry: CTEV underperforms 71.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.21 |
3. Growth
3.1 Past
CTEV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.52%, which is quite impressive.
Looking at the last year, CTEV shows a small growth in Revenue. The Revenue has grown by 0.89% in the last year.
The Revenue has been decreasing by -1.09% on average over the past years.
EPS 1Y (TTM)67.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.56%
Revenue 1Y (TTM)0.89%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%6.71%
3.2 Future
Based on estimates for the next years, CTEV will show a very strong growth in Earnings Per Share. The EPS will grow by 24.87% on average per year.
CTEV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.73% yearly.
EPS Next Y76.87%
EPS Next 2Y35.1%
EPS Next 3Y24.87%
EPS Next 5YN/A
Revenue Next Year2.84%
Revenue Next 2Y3.23%
Revenue Next 3Y3.73%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CTEV. In the last year negative earnings were reported.
Also next year CTEV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
82.86% of the companies in the same industry are more expensive than CTEV, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 10.58 |
4.3 Compensation for Growth
A more expensive valuation may be justified as CTEV's earnings are expected to grow with 24.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.1%
EPS Next 3Y24.87%
5. Dividend
5.1 Amount
No dividends for CTEV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
37.96
+0.51 (+1.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners48.04%
Inst Owner ChangeN/A
Ins Owners6.93%
Ins Owner Change0.62%
Market Cap627.48M
Revenue(TTM)951.00M
Net Income(TTM)-341.68M
Analysts84.44
Price Target90.1 (137.36%)
Short Float %7.3%
Short Ratio3.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.42%
Min EPS beat(2)-15.41%
Max EPS beat(2)2.57%
EPS beat(4)2
Avg EPS beat(4)-5.44%
Min EPS beat(4)-23.58%
Max EPS beat(4)14.65%
EPS beat(8)4
Avg EPS beat(8)-188.45%
EPS beat(12)6
Avg EPS beat(12)-288.48%
EPS beat(16)7
Avg EPS beat(16)-215.53%
Revenue beat(2)2
Avg Revenue beat(2)2.38%
Min Revenue beat(2)2.26%
Max Revenue beat(2)2.51%
Revenue beat(4)3
Avg Revenue beat(4)0.94%
Min Revenue beat(4)-2.88%
Max Revenue beat(4)2.51%
Revenue beat(8)3
Avg Revenue beat(8)-1.92%
Revenue beat(12)5
Avg Revenue beat(12)-1.32%
Revenue beat(16)7
Avg Revenue beat(16)-1.84%
PT rev (1m)15.22%
PT rev (3m)25.59%
EPS NQ rev (1m)-14.2%
EPS NQ rev (3m)-7.21%
EPS NY rev (1m)-3.39%
EPS NY rev (3m)0.78%
Revenue NQ rev (1m)1.41%
Revenue NQ rev (3m)1.41%
Revenue NY rev (1m)1.35%
Revenue NY rev (3m)1.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.66 | ||
| P/FCF | N/A | ||
| P/OCF | 35.54 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.58 |
EPS(TTM)-20.48
EYN/A
EPS(NY)-12.17
Fwd EYN/A
FCF(TTM)-6.79
FCFYN/A
OCF(TTM)1.07
OCFY2.81%
SpS57.53
BVpS-6.16
TBVpS-270.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.85% | ||
| ROE | N/A | ||
| ROCE | 1.04% | ||
| ROIC | 0.82% | ||
| ROICexc | 0.83% | ||
| ROICexgc | 10.68% | ||
| OM | 5.21% | ||
| PM (TTM) | N/A | ||
| GM | 74.72% | ||
| FCFM | N/A |
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
ROICexc(3y)2.48%
ROICexc(5y)N/A
ROICexgc(3y)66.67%
ROICexgc(5y)N/A
ROCE(3y)3.05%
ROCE(5y)N/A
ROICexgc growth 3Y-40.96%
ROICexgc growth 5Y-27.14%
ROICexc growth 3Y-26.84%
ROICexc growth 5Y-14.89%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
F-Score6
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 9.38 | ||
| Cap/Depr | 29.31% | ||
| Cap/Sales | 13.65% | ||
| Interest Coverage | 0.14 | ||
| Cash Conversion | 3.59% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.21 | ||
| Altman-Z | -0.35 |
F-Score6
WACC6.74%
ROIC/WACC0.12
Cap/Depr(3y)25.06%
Cap/Depr(5y)22.79%
Cap/Sales(3y)10.77%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.56%
EPS Next Y76.87%
EPS Next 2Y35.1%
EPS Next 3Y24.87%
EPS Next 5YN/A
Revenue 1Y (TTM)0.89%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%6.71%
Revenue Next Year2.84%
Revenue Next 2Y3.23%
Revenue Next 3Y3.73%
Revenue Next 5YN/A
EBIT growth 1Y-61.12%
EBIT growth 3Y-37.5%
EBIT growth 5Y-23.25%
EBIT Next Year145.66%
EBIT Next 3Y35.58%
EBIT Next 5YN/A
FCF growth 1Y-263.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-89.72%
OCF growth 3Y-35.69%
OCF growth 5Y-17.66%
CLARITEV CORP / CTEV FAQ
Can you provide the ChartMill fundamental rating for CLARITEV CORP?
ChartMill assigns a fundamental rating of 2 / 10 to CTEV.
Can you provide the valuation status for CLARITEV CORP?
ChartMill assigns a valuation rating of 1 / 10 to CLARITEV CORP (CTEV). This can be considered as Overvalued.
What is the profitability of CTEV stock?
CLARITEV CORP (CTEV) has a profitability rating of 3 / 10.
Can you provide the expected EPS growth for CTEV stock?
The Earnings per Share (EPS) of CLARITEV CORP (CTEV) is expected to grow by 76.87% in the next year.